Overview

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Barbara Ann Karmanos Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antibodies
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins
Immunologic Factors
Mitogens